Graviton 4 Oncology 04/2015 Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis AACR Annual MeetingRead More
Graviton 4 Oncology 04/2015 Biomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients AACR Annual MeetingRead More
Graviton 2 Oncology 04/2015 Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 AACR Annual MeetingRead More
natalia 4 Oncology 11/2014 Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 EORTC-NCI-AACR International ConferenceRead More
natalia 4 Oncology 11/2014 Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications EORTC-NCI-AACR International ConferenceRead More
natalia 4 Oncology 04/2014 Efficacy of FASN-selective small molecule inhibitors of preclinical tumor models AACR Annual MeetingRead More
natalia 4 Oncology 10/2013 Characterization of small-molecule FASN inhibitors in preclinical tumor models AACR-NCI-EORTC International ConferenceRead More